Immatics N.V., a clinical-stage biopharmaceutical company, announced that it will present data on its lead cell therapy candidate, IMA203 TCR T-cell therapy targeting PRAME, at the upcoming 2025 ...

Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery ...

Called SUPRAME, this clinical trial of nearly 360 patients will test an engineered T cell receptor (TCR), T cell therapy, called ACTengine® designed by Immatics, a clinical-stage biotechnology ...

About TScan Therapeutics, Inc. TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients ...

Immunocore Holdings' stock has dropped 60% as Kimmtrak faces market saturation, but its pipeline could offer potential. Find ...

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the ...

IMA203 is an autologous, engineered T-cell receptor T-cell therapy (TCR T) that targets PRAME, an intracellular protein displayed as a peptide antigen on the surface of multiple solid tumors via ...

A copy of the presentation materials will be added to the“Publications” section of the Company's website at tscan.com once the presentation has concluded. About TScan Therapeutics, Inc.

WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T ...